Fitbit v. Philips: Federal Circuit Affirms Unpatentability of Portable Monitoring Patent
Fitbit, LLC successfully challenged Koninklijke Philips’ US8868377B2, covering portable monitoring devices and operating methods. The Federal Circuit affirmed the PTAB’s unpatentability finding in a Rule 36 judgment — the case ran 570 days from filing to close.
Federal Circuit kills Philips wearable monitoring patent in Fitbit challenge
Fitbit, LLC — now a Google subsidiary and a leading player in consumer wearables — filed this appeal at the Federal Circuit on 21 October 2022, challenging a PTAB decision concerning Koninklijke Philips’ US8868377B2. The patent, filed under application number US14/076527, protects portable monitoring devices and methods of operating them — technology squarely relevant to the competitive wearable health-monitoring market in which both parties operate.
The Federal Circuit closed the case on 13 May 2024 with a Rule 36 affirmance, the court’s mechanism for affirming a lower tribunal’s decision without issuing a written opinion when the judgment requires no new legal exposition. The underlying PTAB ruling — that the claims of US8868377B2 are unpatentable — therefore stands in full force. For Philips, this means the patent is cancelled and unenforceable; for Fitbit, the freedom-to-operate risk posed by this specific patent is eliminated.
The 570-day duration is consistent with the Federal Circuit’s typical processing window for patent appeals, suggesting no unusual procedural complications. Because the court issued a Rule 36 judgment, no written reasoning is publicly available, leaving the specific invalidity grounds — whether anticipation, obviousness, or otherwise — and any claim-by-claim analysis confined to the PTAB record below. Practitioners seeking the full evidentiary basis must review the underlying PTAB proceeding.
Filing to Unpatentable in 570 days
570 days — slightly above the Federal Circuit’s median disposition time for inter partes appeals
Federal Circuit affirms: what the Rule 36 judgment means for both parties
Rule 36 affirmance: a silent but final verdict
A Federal Circuit Rule 36 judgment affirms the tribunal below — here the PTAB — without issuing a written opinion. The court applies this mechanism when the judgment raises no novel legal question requiring public guidance. It is not a procedural shortcut; it carries full precedential weight between the parties. The PTAB’s unpatentability finding is now final, and no reasoning from the Federal Circuit supplements the record.
No written opinion issuedPhilips loses US8868377B2 — patent is cancelled
The affirmance confirms that US8868377B2 is unpatentable, meaning its claims are cancelled and no longer enforceable. Philips cannot assert this patent against Fitbit or any third party. Any licensing programme built on this patent is effectively extinguished. Philips retains its broader portfolio in wearable and health-monitoring technology, but this specific claim scope is gone. The Rule 36 posture also forecloses further Federal Circuit review on these claims.
Patent cancelled, unenforceableFitbit secures freedom to operate in portable monitoring
Fitbit’s successful invalidity challenge removes one patent vector that Philips could have deployed in district court infringement actions. With US8868377B2 cancelled, Fitbit’s wearable device portfolio faces no liability exposure under this patent. The affirmance also raises the practical bar for Philips to re-litigate these same claims — estoppel principles from the PTAB proceeding would apply to any future challenge to the same prior art combinations.
FTO risk eliminated for FitbitWearable monitoring IP landscape: a patent thins
The cancellation of a Philips portable monitoring patent is commercially significant in a sector where wearable health-tech IP is actively litigated and licensed. Competitors and new market entrants can now design around this claim scope without licence risk. It also signals that the PTAB remains a viable and final forum for challenging broad platform patents in the consumer health-monitoring space — and that the Federal Circuit will affirm such outcomes without adding new guidance when the record is clear.
Reduced IP risk for wearables sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Fitbit, LLC | Company | Consumer wearables company — appellant challenging validity of Philips’ US8868377B2Search in Eureka ↗ |
| Defendant | Koninklijke Philips | Individual | Philips and Philips North America — health-tech multinationals defending portable monitoring patentSearch in Eureka ↗ |
| Co-Defendant | Philips North America, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexa Lowman | Attorney | Counsel for Fitbit, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel Zeilberger | Attorney | Counsel for Fitbit, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Joseph Palys | Attorney | Counsel for Fitbit, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Naveen Modi | Attorney | Counsel for Fitbit, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Stephen Blake Kinnaird | Attorney | Counsel for Fitbit, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Paul Hastings, LLP | Law Firm | Representing Fitbit, LLCSearch in Eureka ↗ |
| Defendant counsel | Justin J. Oliver | Attorney | Counsel for Koninklijke PhilipsSearch in Eureka ↗ |
| Defendant counsel | Sean M. McCarthy | Attorney | Counsel for Koninklijke PhilipsSearch in Eureka ↗ |
| Defendant law firm | Venable LLP | Law Firm | Representing Koninklijke PhilipsSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The terse ‘AFFIRMED. See Fed. Cir. R. 36.’ verdict is the Federal Circuit’s standard form for affirming without opinion. It signals that the panel found no reversible error in the PTAB’s unpatentability determination — the legal standard on appeal requires showing the PTAB’s factual findings were unsupported by substantial evidence, or that its legal conclusions were erroneous. Neither threshold was met. The cancellation of US8868377B2 is therefore final at this appellate level, with no new claim construction or invalidity guidance generated for the broader market.
US8868377B2 — Portable monitoring devices and methods of operating same
US8868377B2, filed under application number US14/076527 and assigned to Koninklijke Philips, covers portable monitoring devices and their methods of operation — a broad technical footprint encompassing sensor-equipped wearable devices that track physiological or activity data. The patent sits within the intersection of embedded sensing hardware, signal processing, and user-device interaction protocols, all of which are foundational to modern fitness trackers and health-monitoring wearables. Its now-cancelled claims had the potential to reach a wide range of competing product architectures.
Strategically, US8868377B2 represented a platform-level patent in the wearable health segment — the kind of asset that can generate licensing leverage or underpin infringement actions against device makers shipping portable monitoring hardware. Philips has historically maintained a substantial health-technology IP portfolio, and this patent’s cancellation removes one enforcement vector in a competitive space that includes Fitbit (Google), Apple, Garmin, and Samsung. Companies with products involving portable biometric monitoring should assess whether related Philips patents in the same priority family present residual risk.
Should you run an FTO against US8868377B2 and its Philips family patents?
US8868377B2 is cancelled — it no longer poses a direct infringement risk. However, R&D and product legal teams developing portable monitoring devices, fitness wearables, or health-sensing hardware should not stop at this single patent. Philips’ portfolio in this space is extensive, and continuation patents, divisional filings, or related applications sharing the same priority chain may carry overlapping claim scope that remains in force. Any product team shipping wearable monitoring technology should run a full FTO against the Philips wearable patent family.
PatSnap Eureka’s FTO Search Agent can map the full priority family of US8868377B2, identify live continuation and divisional patents, and cross-reference your product’s feature set against surviving claim language. The agent surfaces potential infringement vectors that a manual search would miss, and flags any co-pending applications that could mature into enforceable rights. For wearable health-tech teams operating in Philips’ technology footprint, an Eureka FTO audit is a proportionate and efficient first step.
Run a freedom-to-operate analysis on US8868377B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit IPR appeals in portable monitoring and wearable health tech
Cases where the Federal Circuit reviewed PTAB unpatentability rulings on wearable monitoring and health-sensing device patents, including other Fitbit and Philips IP disputes.
What this case signals for the wearable health-tech IP landscape
A cancelled Philips monitoring patent and a silent Federal Circuit affirmance carry lessons for every IP team operating in consumer health wearables.
PTAB remains a powerful — and final — tool against broad wearable patents
Fitbit’s result demonstrates that well-constructed IPR petitions targeting portable monitoring patents can survive full Federal Circuit review. With the court affirming under Rule 36, the PTAB record was evidently sufficiently robust. IP teams defending against wearable platform patents should treat PTAB as a primary strategy, not a fallback.
Rule 36 judgments create asymmetric information risk for third parties
Because no written opinion was issued, the specific invalidity rationale — prior art relied on, claim construction adopted — remains in the PTAB record only. Competitors and licensees who want to understand the precise scope of cancelled claims must dig into the underlying proceeding. PatSnap Eureka can map the PTAB file history to surface that analysis.
Fitbit v Koninklijke — key questions answered
The Federal Circuit affirmed the PTAB’s ruling that US8868377B2 — Philips’ patent on portable monitoring devices and methods of operating same — is unpatentable. The court issued a Rule 36 judgment on 13 May 2024, meaning no written opinion was published and the PTAB cancellation stands in full.
A Rule 36 affirmance confirms the lower tribunal’s decision without a written opinion. It signals the panel found no reversible error in the PTAB’s unpatentability determination. For US8868377B2, the practical effect is that the patent’s claims are permanently cancelled and unenforceable against any party, including Fitbit and third-party wearable device manufacturers.
Philips cannot assert US8868377B2 — it is cancelled. However, Philips retains its broader wearable and health-technology portfolio. Related continuation or divisional patents sharing the US8868377B2 priority chain may survive and cover overlapping subject matter. Parties should conduct a full family-level FTO to identify any live Philips claims that could still be asserted.
Under 35 U.S.C. § 315(e), a petitioner who has received a final written PTAB decision is estopped from asserting in subsequent proceedings that a claim is invalid on any ground the petitioner raised or reasonably could have raised during the IPR. This means Fitbit’s ability to challenge related Philips claims using the same or available prior art combinations may be constrained in future PTAB petitions or district court proceedings.
Fitbit was represented by Paul Hastings, LLP, with attorneys including Naveen Modi, Joseph Palys, Daniel Zeilberger, Stephen Blake Kinnaird, and Alexa Lowman. Philips and Philips North America were represented by Venable LLP, with Justin J. Oliver and Sean M. McCarthy appearing as counsel of record.
PatSnap Eureka searches patents and litigation data to answer instantly.